BC Partners Invests in InfoRLife IV Infusion Bag Platform

BC Partners has entered into a significant agreement to acquire a co-control stake in InfoRLife, a specialized developer and manufacturer of ready-to-use intravenous infusion bags. This strategic investment, originating from BC Partners Fund XII, aims to fuel InfoRLife's expansion and enhance its capabilities in the critical pharmaceutical sector. The transaction sees BC Partners partnering with founder and CEO Sergio Dusci and the founding families of ACS Dobfar, who will maintain ongoing involvement in the business.

The influx of capital and strategic expertise from BC Partners, a firm managing approximately €35 billion, is expected to propel InfoRLife's growth trajectory. The company, established in 2002 as a division of ACS Dobfar, operates state-of-the-art facilities across Switzerland, Romania, and Tunisia. InfoRLife distinguishes itself as a unique business-to-business entity focused exclusively on the development and contract manufacturing of pre-filled IV infusion bags, a segment experiencing heightened demand due to its inherent safety and efficiency benefits.

Ready-to-use IV infusion bags offer a compelling solution for healthcare providers by delivering pre-formulated medications at the correct concentration, thereby streamlining clinical workflows and minimizing the risk of errors associated with manual drug preparation. This innovation is particularly valuable in environments facing staffing pressures and the need for standardized medication administration. The market for such advanced drug delivery systems is expanding as hospitals prioritize patient safety and operational efficiency in injectable medicine delivery.

InfoRLife's comprehensive service offering spans the entire product lifecycle, from initial formulation and regulatory dossier development to commercial-scale manufacturing and out-licensing. This end-to-end capability allows pharmaceutical clients to leverage InfoRLife's specialized expertise and infrastructure, enabling them to focus on core commercialization and distribution strategies. The development of a robust pharmaceutical dossier, a critical component for regulatory approval, requires meticulous formulation work, extensive stability testing, and rigorous manufacturing validation – areas where InfoRLife excels.

The partnership between BC Partners and InfoRLife, bolstered by the continued participation of ACS Dobfar, is set to drive significant advancements. Future initiatives will concentrate on bolstering research and development efforts, broadening the company's product portfolio to encompass additional therapeutic areas, and optimizing manufacturing and operational processes. Furthermore, the shareholders are exploring strategic acquisitions to enhance product offerings, technological capabilities, manufacturing capacity, and geographic reach, aiming to solidify InfoRLife's position as a leader in the specialized IV infusion market.

This investment aligns with BC Partners' established strategy of targeting defensive growth businesses within the mid-market. The healthcare manufacturing sector, characterized by consistent demand tied to patient care, fits this profile, although companies must navigate regulatory and operational complexities. InfoRLife's focus on complex medicines, where development and manufacturing hurdles limit competition, presents a particularly attractive opportunity for sustained growth and market leadership.